Pre-planned secondary analysis of the GIVE MOVE trial in 137 children and adolescents with HIV viraemia on ART: 58% had all three drugs predicted active; 12% had resistance to their core agent, suggesting most viraemia was not explained by resistance.
Secondary analysisn = 137
Schönenberger et al. HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial